Camp4 wins Australian clearance for Phase 1/2 CMP-002 trial in SYNGAP1-related disorder - CAMP News | RalliesCamp4 wins Australian clearance for Phase 1/2 CMP-002 trial in SYNGAP1-related disorder
C
CAMP• Australian clearance for first-in-human CMP-002 trial
- Camp4 Therapeutics won Australian TGA clearance to start a Phase 1/2 first-in-human trial of CMP-002 for SYNGAP1-related disorder.
- The clearance triggers eligibility for up to USD 50 million in additional private placement proceeds under a September 9, 2025 agreement.
- Closing is expected within five business days, subject to customary conditions.
ENHA
•
